Reconnecting

The current page stays visible while onset.to reconnects in the background.

GH Research reports GH001 trial results, plans pivotal depression programs and posts third-quarter 2026 financial results

Open original

GH Research plans pivotal studies of inhaled mebufotenin candidate GH001 for treatment-resistant and postpartum depression using a new aerosol device designed to deliver one fixed dose per visit. In a healthy-volunteer study, seven of eight participants at the planned pivotal dose reached a peak experience. The company expects an FDA end-of-Phase 2 meeting in early 2027, followed by initiation of the treatment-resistant depression program, subject to regulatory alignment. In an open-label postpartum depression trial, all 10 patients were in remission at two hours, Day 2 and Day 8; a pivotal program is targeted for the second half of 2027. The company cautions that early results may not predict pivotal trial outcomes. It reported $350.6 million in cash, equivalents and marketable securities and a $12.5 million quarterly net loss.